Pfizer recalls 104,000 bottles of antidepressant Effexor XR..... Novartis sees start of $2B dermatology opportunity with new EU Xolair approval..... Gilead's Sovaldi sales through the roof already, analyst predicts at least $8B this year..... Bristol-Myers Squibb cuts more costs by whacking 160 jobs in Ireland..... EU suggests new warning for same sleeping pill that landed a Kennedy before a jury..... AstraZeneca says Nexium pills with Ranbaxy ingredient are safe to use..... Omeros reports additional positive data from OMS824 Phase IIa schizophrenia clinical trial..... European Commission grants conditional approval to Janssen's TB drug Sirturo..... Pfizer voluntarily recalls depressive disorder drug..... Debiopharm to acquire products or companies to expand activities at Martigny manufacturing facility in Switzerland..... Navidea Biopharmaceuticals closes $30m loan with Oxford Finance..... Biostar Pharmaceuticals partners with Shaanxi University of Chinese Medicine to co-develop liver cancer drug..... NeoStem enters into sponsored research collaboration with Massachusetts Eye and Ear/Schepens Eye Research Institute..... Omeros reports additional positive data from OMS824 Phase IIa schizophrenia clinical trial..... Regulus Therapeutics initiates dosing of RG-101 in Phase I study..... Regulus Therapeutics initiates dosing of RG-101 in Phase I study..... ProBioGen grants license of GlymaxX ADCC enhancement technology to Merus..... Janssen Biotech to start Phase III daratumumab trial to treat myeloma patients..... Alchemia licenses two anticancer drug candidates from CTx..... UPDATED: Endo finally wins a Low-T drug nod, but safety dispute could snarl its launch..... Italian prosecutors jump into Roche, Novartis case with fraud probe..... Merck KGaA shores up Rebif defenses to fend off new MS rivals..... Novartis nabs a new anti-hives use for Xolair in the EU..... On India trip, U.S. diplomat cites 'concern' about anti-patent actions..... Baxter scrambles to retrieve glucose bags after reports of patient reactions..... Quanticate expands global operations for biostatistics and programming in clinical trials..... Metabolon enters into collaboration agreement with Human Longevity to provide metabolomic profiling services..... RXi Pharmaceuticals gets US patent related to self-delivering technology to treat fibrotic disorders..... ZS Pharma closes $55m financing to develop new treatments for Hyperkalemia..... DARA BioSciences signs Medicare Part D Prescription Drug Agreement with WellCare..... Agenus to advance three checkpoint modulator antibodies into development..... Antigen Express receives patents for vaccines targeting HPV induced cancers and influenza..... Quanticate expands global operations for biostatistics and programming in clinical trials..... Metabolon enters into collaboration agreement with Human Longevity to provide metabolomic profiling services..... RXi Pharmaceuticals gets US patent related to self-delivering technology to treat fibrotic disorders..... Sagent Pharmaceuticals initiates voluntary recall of zoledronic acid injection..... BioSyent signs licence, distribution agreement for new gastrointestinal health product..... Proteostasis extends collaboration with CFFT for new therapies to treat cystic fibrosis..... Harlan CRS, Bertin Pharma enter drug development agreement..... ThromboGenics to begin Phase IV trial of Jetrea in US to treat VMA/VMT..... Medicaid health plans demand state help to cover pricey new hep C drugs..... Amarin sues AstraZeneca ahead of launch of Vascepa competitor..... Italy levies eye-opening antitrust fines against Roche, Novartis over Lucentis..... Lilly's end of the road on Evista looms with FDA nod for Teva generic..... Sanofi widens marketing team for slow starter Kynamro..... In SGLT2 diabetes fight, Lilly's empagliflozin loss is J&J and AstraZeneca's gain..... Omeros submits IND application to FDA to initiate OMS721 Phase II clinical program for TMAs..... Argos Therapeutics presents new data from clinical research for AGS-004 patient-specific immunotherapy in HIV treatment..... Xenetic Biosciences opens corporate headquarters and R&D facility in Massachusetts..... Synageva BioPharma issued US patent for treatment of LAL deficiency..... Celerion announces expansion of clinical operations to South Korea..... ChanTest opens new laboratory facilities for expanded cell and molecular biology services..... Takeda fesses up to improperly marketing its blood-pressure blockbuster, Blopress..... Ohr Pharmaceutical and CSHL announce joint venture to develop trodusquemine and related analogs..... Genocea Biosciences announces collaboration to characterize anti-tumor T cell responses in melanoma patients..... Heat Biologics begins dosing patients in Phase I/II bladder cancer trial of HS-410..... Covance and Business Review FREE Webinar Series Offers Specialized Content for Pharma Industry Professionals..... Teva Pharmaceuticals launches Adasuve in US for agitation treatment..... Perrigo buys OTC products from Aspen Global for $51m..... Cumberland buys Astellas Pharma's prescription brand Vaprisol..... Takeda fesses up to improperly marketing its blood-pressure blockbuster, Blopress..... Sanofi slapped with ?28M bribery fine for former German employees' scheme..... Lilly, Pfizer and Merck slash doctor payments, but J&J and Forest shell out more..... Why does Alexion's Soliris cost $500K-plus? U.K. gatekeepers want to know..... Roche's M&A budget opens up as it pays off Genentech deal debt..... Teva keeps battling Natco over generic of blockbuster Copaxone..... Acucela closes patient enrollment in Phase IIb/III trial of emixustat hydrochloride..... Galena Biopharma launches Galena Patient Services..... Simulations Plus signs research collaboration agreement with FDA..... IntelGenx and RedHill Biopharma submit response to FDA CRL for VersaFilm product..... Vida Canada contracts to purchase production plant..... Cardium announces strategic collaboration and funding With Taxus Pharmaceuticals..... The top 10 pharma companies by 2013 revenue..... MEI Pharma's leukemia drug Pracinostat gets FDA orphan status..... InterMune supports European Patient Charter on idiopathic pulmonary fibrosis..... Norges Bank?s annual financial statements for 2013..... Kyowa Hakko Kirin to start construction of new IK8 research building at Fuji Research Park..... Galena Biopharma gets patent acceptance in Australia for NeuVax..... Eisai starts Phase III breast cancer trial of eribulin mesylate versus paclitaxel..... GSK submits sNDA for Promacta to FDA for severe aplastic anaemia treatment..... Teva's new Copaxone formula could be a hard sell with payers..... Generic makers to FDA: Labeling rule risky for patients, adds $4B in annual costs..... No merger talk here: Novartis just wants to be friends with Roche, chairman says..... Questcor, short sellers trade attacks..... Pfizer keeps rolling with $1B bid for OTC Lipitor..... German lawmakers drag pricing freeze out to 2017..... Takeda files NDA for TAK-438 in Japan to treat acid-related diseases..... Otsuka Pharmaceutical signs five-year extension of MOU with South Korea Ministry of Health and Welfare..... Perrigo and Transition Therapeutics modify development and commercialization rights of ELND005 program..... Biotie in advanced discussions for partnership for further development of SYN120..... CHMP issues positive opinion for tablet formulation of Merck?s Noxafil..... Astellas secures exclusive rights to commercialize isavuconazole in US and Canada..... Salix, RedHill enter license agreement for solid bowel prep product RHB-106..... Astellas' mucormycosis drug Isavuconazole gets FDA QIDP designation..... La Jolla licenses GW technology for new HRS compound LJPC-501..... Allergen starts Phase IIb clinical trial for peanut allergy oral immunotherapy..... Endo loss widens, R&D chief departs amid regulatory struggles..... New drugs in hand, Bayer's pharma sales leap ahead..... Pradaxa, Xarelto makers dispute purported Eliquis safety edge..... Drugmakers, FDA need a SWAT team approach on shortages, group says..... Amarin lashes out at FDA with lawsuit over Vascepa exclusivity..... Bayer to acquire Chinese OTC drug-maker Dihon..... GenScript launches GenPlus next-generation gene synthesis technology..... Mast Therapeutics completes acquisition of Aires Pharmaceuticals..... Novavax announces extension of contract with HHS-BARDA..... Pernix signs agreement with Osmotica Pharmaceutical to promote Khedezla tablets..... Karyopharm Therapeutics announces initiation of Phase I study of Selinexor in Singapore..... CEL-SCI reports 146 patients enrolled in Phase III immunotherapy head and neck cancer trial..... Ignyta submits IND application to FDA for oral tyrosine kinase inhibitor..... RSS NEWSFEED....

Welcome to
The Academy of
Pharmaceutical Sciences

The Academy of Pharmaceutical Sciences is the professional body for the Pharmaceutical Sciences in United Kingdom. A Pharmaceutical Scientist is an individual who contributes to bringing a new drug from concept through to a medicinal product. This includes, but is not exclusive to, individuals in academia, industry, regulation, clinical research and manufacturing.

The mission of the Academy of Pharmaceutical Sciences is to champion innovation and opportunity in Pharmaceutical Sciences for the delivery of medicines.

In order to achieve this mission, our aims are to:

Promote the Pharmaceutical Sciences to stakeholders to facilitate understanding and achieve engagement
Share learning, drive collaboration, partnership and innovation
Deliver insights into industry and academic roles for aspiring scientists

Latest News

Skin Forum 2014, September 4th and 5th, Prague, Czech Republic.
MONDAY, 24 FEBRUARY 2014
The final programme and registration forms for this year's joint Skin Forum - APV meeting are now available on the APV website at the following link: http://www.apv-mainz.de/english/seminars/events/events/ This year's programme features a dedicated industrial transdermal formulation session. For any queries related to the meeting please contact majella.lane@btinternet.com .

APS Amorphous by Design 2014
FRIDAY, 14 FEBRUARY 2014
Characterisation and Processing of Amorphous Materials Fundamental characterisation of amorphous materials to move away from a trial and error approach and ensure robust manufacturing Bradford University Monday 28th and Tuesday 29th April 2014 Amorphous materials provide a great opportunity to enhance the performance of pharmaceutical, especially for poorly soluble materials. Due to their challenges in understanding stability and manufacture they provide a great challenge to provide reproducible performance. This meeting will provide up to date knowledge and opportunities to share learning and experiences in the area of processing, analysis and understanding amorphous materials. The event is suitable for both scientists and leaders in the pharmaceutical arena as well as other processing industries. As part of the programme there will be a number of round table discussions to take opinion/guidance from attendees to discuss challenges observed from other companies. For more information, please visit the webpage here: http://www.apsgb.co.uk/events/20140428/default.asp . . . .

GSK Emerging Scientist Award 2014
THURSDAY, 30 JANUARY 2014
GlaxoSmithKline and the Academy of Pharmaceutical Sciences present the GSK Emerging Scientist Award and invite post-graduate and post-doctoral researchers to submit an application. Prize The winner will receive a Commemorative Award, £1,000 in prize money and an invitation to present the GSK Emerging Scientist Award Lecture on their work at APS PharmSci 2014. Entry Criteria Entrants are welcome from researchers from across the globe in academia, industry, public service or other scientific establishments. The individual applicant should have demonstrated, through published work, a significant innovation which has the potential for application within the pharmaceutical industry. Applicants must be within 10 years of commencing their first research position on the closing date to be eligible. Time spent in undergraduate education is excluded. Clarification on eligibility can be sought by submitting a copy of your CV to the APS at info@apsgb.org. Submission Criteria Applicants are requested to submit their CV and a synopsis of their research of not more than 1000 words, focussing on its importance to the pharmaceutical industry. Diagrams and images will account for 50 words. Any references used should be cited fully using the Harvard system. Entries should be submitted via email to Alan Ramsay at info@apsgb.org. including ‘Emerging Scientist Award 2014’ in the subject field. Your email application must include your full name and postal address, a contact telephone number, your email, and your institution or organisation’s name. Entries will be judged by an APS panel. Closing Date for Entries 28th Feb 2014

APS / GSK National Hot Topic Award 2014
THURSDAY, 23 JANUARY 2014
GlaxoSmithKline and the Academy of Pharmaceutical Sciences present the GSK National Hot Topic Award and invite students to submit a short article on the chosen topic. This year the topic is:. ‘Personalised medicine could transform healthcare. Discuss the strategies that the pharmaceutical industry and healthcare providers can adopt to provide personalised medicines.’. Entries will be judged by an APS panel on the quality of research and ideas, originality, structure, grammar, spelling, style and vocabulary.. . Prize. The winner will receive an award of £500 and conference attendance at the APS Industrial Insights Conference 2014 (including accommodation).. . Topic. Traditionally pharmaceutical companies have developed medicines based on known disease mechanisms. These are then prescribed to large patient populations based on disease state. This results in the successful treatment of the majority of patients but may offer little benefit or significant side effects for sub-populations of patients.. An increased genetic understanding of disease has made it possible to adopt approaches to prevention and treatment of disease specific to a subpopulation of individuals, thus increasing patient benefit and reducing side effects. This approach is known as personalised or stratified medicine and has the mantra 'the right drug for the right patient at the right time'. For this approach to deliver there are multiple challenges to be met right across the healthcare sector, including access to and use of genetic data, development of diagnostics and biomarkers, conduct of clinical trials in small subpopulations and the possible stratification of already licensed medicines.. In no more than 1000 words discuss the strategies that the pharmaceutical industry and healthcare providers can adopt to provide personalised medicines.. . . Entry Criteria . Entrants must be current UK based Undergraduate, Masters or PhD students. Articles should be no more than 1000 words including appendices. Diagrams and images will account for 50 words. Any references used should be cited fully using the Harvard system. . Entries should be submitted via email to info@apsgb.org including ‘National Hot Topic Submission 2014’ in the subject field. . Your email application must include your full name and postal address, a contact telephone number, your academic email, your degree-level, field of study and your University’s name. . Closing Date for Entries 28th Feb 2014.

Upcoming Events

APS Developability Course
18 - 19 March 2014

APS Board Meeting
2 - 3 April 2014

APS Industrial Insights 2014
16 - 17 April 2014

APS Amorphous by Design 2014
28 - 29 April 2014

APS Board Meeting
8 - 9 July 2014

Vacancies

View all Vacancies
Advertise your job vacancies